BR112023018330A2 - Métodos para predição de resposta ao tratamento em colite ulcerativa - Google Patents
Métodos para predição de resposta ao tratamento em colite ulcerativaInfo
- Publication number
- BR112023018330A2 BR112023018330A2 BR112023018330A BR112023018330A BR112023018330A2 BR 112023018330 A2 BR112023018330 A2 BR 112023018330A2 BR 112023018330 A BR112023018330 A BR 112023018330A BR 112023018330 A BR112023018330 A BR 112023018330A BR 112023018330 A2 BR112023018330 A2 BR 112023018330A2
- Authority
- BR
- Brazil
- Prior art keywords
- inflammatory bowel
- treatment
- bowel disease
- methods
- ulcerative colitis
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 206010009900 Colitis ulcerative Diseases 0.000 title abstract 2
- 201000006704 Ulcerative Colitis Diseases 0.000 title abstract 2
- 230000004044 response Effects 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 5
- 238000011269 treatment regimen Methods 0.000 abstract 3
- 239000000090 biomarker Substances 0.000 abstract 2
- 238000001514 detection method Methods 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000004043 responsiveness Effects 0.000 abstract 1
- 239000000523 sample Substances 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
métodos para predição de resposta ao tratamento em colite ulcerativa. a presente invenção refere-se a biomarcadores que podem ser usados para a detecção ou diagnóstico de estados doentios, de preferência estados de doença inflamatória intestinal, a identificação de um regime de tratamento de doença inflamatória intestinal e/ou para indicar a capacidade de resposta ao regime de tratamento de doença inflamatória intestinal em um indivíduo. são descritas também sondas capazes de detectar os biomarcadores e métodos e kits relacionados para determinar estados de doença inflamatória intestinal e/ou identificação de regimes de tratamento para os estados de doença inflamatória intestinal.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163160199P | 2021-03-12 | 2021-03-12 | |
PCT/IB2022/052166 WO2022190036A2 (en) | 2021-03-12 | 2022-03-10 | Methods for predicting treatment response in ulcerative colitis |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112023018330A2 true BR112023018330A2 (pt) | 2023-12-05 |
Family
ID=80786892
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112023018330A BR112023018330A2 (pt) | 2021-03-12 | 2022-03-10 | Métodos para predição de resposta ao tratamento em colite ulcerativa |
Country Status (11)
Country | Link |
---|---|
US (1) | US20220291238A1 (pt) |
EP (1) | EP4305425A2 (pt) |
JP (1) | JP2024509953A (pt) |
KR (1) | KR20230156746A (pt) |
CN (1) | CN117295952A (pt) |
AU (1) | AU2022233979A1 (pt) |
BR (1) | BR112023018330A2 (pt) |
CA (1) | CA3213280A1 (pt) |
IL (1) | IL305808A (pt) |
MX (1) | MX2023010694A (pt) |
WO (1) | WO2022190036A2 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117517675A (zh) * | 2022-09-23 | 2024-02-06 | 上海市第十人民医院 | 蛋白生物标志物saa2在克罗恩病临床诊断中的应用 |
CN117949656B (zh) * | 2024-03-22 | 2024-05-28 | 吉林省继明生物科技有限责任公司 | 一种细胞色素p4502d6代谢酶检测试剂盒及其应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7943310B2 (en) * | 2006-08-30 | 2011-05-17 | Centocor Ortho Biotech Inc. | Methods for assessing response to therapy in subjects having ulcerative colitis |
CA2676790A1 (en) * | 2007-02-22 | 2008-08-28 | Genentech, Inc. | Methods for detecting inflammatory bowel disease |
CN104159919A (zh) * | 2011-11-23 | 2014-11-19 | 安姆根有限公司 | 使用抗干扰素γ抗体的治疗方法 |
GB201521357D0 (en) * | 2015-12-03 | 2016-01-20 | Univ Liverpool | Methods for predicting response to anti-TNF therapy |
GB201611738D0 (en) * | 2016-07-05 | 2016-08-17 | Cambridge Entpr Ltd | Biomarkers for inflammatory bowel disease |
WO2020104705A2 (en) * | 2018-11-23 | 2020-05-28 | Katholieke Universiteit Leuven | Predicting a treatment response in inflammatory bowel disease |
WO2020113116A1 (en) * | 2018-11-29 | 2020-06-04 | Cedars-Sinai Medical Center | Methods of stratifying and treating a sub-population of inflammatory bowel disease patients |
CN110174513A (zh) * | 2019-04-15 | 2019-08-27 | 中山大学附属第一医院 | Tgm2在制备监测克罗恩病疾病活动的生物标志物中的应用 |
EP4015651A1 (en) * | 2020-12-17 | 2022-06-22 | Koninklijke Philips N.V. | Treatment prediction and effectiveness of anti-tnf alpha treatment in ibd patients |
-
2022
- 2022-03-10 EP EP22711330.5A patent/EP4305425A2/en active Pending
- 2022-03-10 AU AU2022233979A patent/AU2022233979A1/en active Pending
- 2022-03-10 US US17/691,277 patent/US20220291238A1/en active Pending
- 2022-03-10 CA CA3213280A patent/CA3213280A1/en active Pending
- 2022-03-10 WO PCT/IB2022/052166 patent/WO2022190036A2/en active Application Filing
- 2022-03-10 CN CN202280034523.0A patent/CN117295952A/zh active Pending
- 2022-03-10 BR BR112023018330A patent/BR112023018330A2/pt unknown
- 2022-03-10 MX MX2023010694A patent/MX2023010694A/es unknown
- 2022-03-10 IL IL305808A patent/IL305808A/en unknown
- 2022-03-10 KR KR1020237034588A patent/KR20230156746A/ko unknown
- 2022-03-10 JP JP2023555487A patent/JP2024509953A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2022233979A1 (en) | 2023-10-26 |
EP4305425A2 (en) | 2024-01-17 |
IL305808A (en) | 2023-11-01 |
CN117295952A (zh) | 2023-12-26 |
WO2022190036A2 (en) | 2022-09-15 |
JP2024509953A (ja) | 2024-03-05 |
WO2022190036A3 (en) | 2022-10-20 |
US20220291238A1 (en) | 2022-09-15 |
AU2022233979A9 (en) | 2023-11-02 |
KR20230156746A (ko) | 2023-11-14 |
CA3213280A1 (en) | 2022-09-15 |
MX2023010694A (es) | 2023-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112023018330A2 (pt) | Métodos para predição de resposta ao tratamento em colite ulcerativa | |
BR112022019754A2 (pt) | Ensaios para detecção de sars-cov-2 | |
Sipponen et al. | Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease | |
Leligdowicz et al. | Validation of two multiplex platforms to quantify circulating markers of inflammation and endothelial injury in severe infection | |
BR112014007214A8 (pt) | Método para determinar a probabilidade de que um indivíduo tenha risco elevado de um evento cardiovascular, método para avaliação do risco de um evento cardiovascular futuro e método implementado por computador para avaliação do risco de um evento cardiovascular | |
Swale et al. | Calprotectin and lactoferrin faecal levels in patients with Clostridium difficile infection (CDI): a prospective cohort study | |
BR112022019764A2 (pt) | Ensaios para detecção de sars-cov-2 | |
RU2018142294A (ru) | Усовершенствованное устройство и способ тестирования на беременность | |
Trembling et al. | Performance of Enhanced Liver Fibrosis test and comparison with transient elastography in the identification of liver fibrosis in patients with chronic hepatitis B infection | |
Dinkelaar et al. | Global coagulation tests: their applicability for measuring direct factor Xa-and thrombin inhibition and reversal of anticoagulation by prothrombin complex concentrate | |
Miao et al. | Assessment of peritoneal microbial features and tumor marker levels as potential diagnostic tools for ovarian cancer | |
AR103935A1 (es) | Métodos de detección y cuantificación de il-13 y sus usos en el diagnóstico y tratamiento de enfermedades asociadas a th-2 | |
Malíčková et al. | Serum trough infliximab levels: a comparison of three different immunoassays for the monitoring of CT-P13 (infliximab) treatment in patients with inflammatory bowel disease | |
Liu et al. | Evaluation of droplet digital PCR for quantification of SARS-CoV-2 Virus in discharged COVID-19 patients | |
Cajander et al. | Quantitative real-time polymerase chain reaction measurement of HLA-DRA gene expression in whole blood is highly reproducible and shows changes that reflect dynamic shifts in monocyte surface HLA-DR expression during the course of sepsis | |
Abdelkader et al. | Serum procalcitonin in Egyptian patients with acute meningitis and a negative direct cerebrospinal fluid examination | |
BR112018073178A2 (pt) | método, matriz e uso dos mesmos | |
Shim et al. | Diagnostic value of the Vesikari Scoring System for predicting the viral or bacterial pathogens in pediatric gastroenteritis | |
Pang et al. | Discovery and validation of prognostic biomarker models to guide triage among adult dengue patients at early infection | |
Landewé | Predictive markers in rapidly progressing rheumatoid arthritis. | |
Li et al. | Determining procalcitonin at point-of-care; A method comparison study of four commercial PCT assays | |
Knauer et al. | Interim analysis of the clinical performance of five SARS-Cov-2 serology assays | |
BR112022018863A2 (pt) | Sistema e método para medir a concentração de analito em fluidos corporais | |
De Leo et al. | Circulating PV-1 as a marker of celiac disease-associated liver injury | |
BR112012008336A2 (pt) | sondas de ácido nucleico peptídico, kit e método para detectar helicobacter pylori e / ou perfil de resistência à claritromicina e aplicações |